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ABSTRACT
Introduction: Acne is a chronic inflammatory
disease. Key to a patient’s success on fixed-dose
adapalene–benzoyl peroxide (BPO) gel is
ensuring adherence. Use of a pump system to
deliver a pre-measured amount of gel with each
pressure enables application of a more
consistent dose vs. the tube, which should
improve adherence. In the present study, we
evaluate patient preference for two different
containers for dispensing adapalene–BPO gel.
Methods: In this 15-day, open-label study, 300
subjects were asked to treat their acne using
fixed-dose adapalene 0.1%–BPO 2.5% gel
dispensed in either a tube or a pump once-
daily for up to 7 days. At week 1, subjects
switched to the alternative packaging design
for the same timeframe. At the end of the
treatment period, subjects were asked to
complete a subject preference survey.
Results: Among subjects completing the survey
(n = 291), 79.0% (n = 230) preferred the pump
for dispensing adapalene–BPO gel and 21.0%
(n = 61) preferred the tube (p\0.001). The top
three characteristics of the pump were that it
was easy to use (89.0%; n = 259/291), clean
(73.2%; n = 213/291) and convenient (69.4%;
n = 202/291). When asked to rate their
experience with using the pump, 91.8%
(n = 267/291; p\0.001) of subjects reported
being satisfied on a self-assessment scale. The
majority of subjects stated they would tell their
doctor about their preference for the pump next
time adapalene–BPO gel was prescribed (76.6%;
n = 223/291; p\0.001) and would prefer the
pump if both containers cost the same amount
(80.1%; n = 233/291; p\0.001).
Conclusion: Patients prefer using a pump
instead of a tube to dispense adapalene–BPO
gel. This delivery mechanism helps to ensure
consistent application and thus may improve
patient adherence to the prescribed acne
treatment regimen.
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INTRODUCTION
Acne is a chronic inflammatory disease of the
pilosebaceous unit, with a long duration and a
pattern of recurrence or relapse [1, 2]. An
individual’s adherence to their medication has
a prominent role in the success of any acne
therapy [1]. However, adherence to acne
treatment regimens is traditionally poor [3, 4].
For example, one large study involving 3,339
acne subjects from the Americas, Europe and
Asia demonstrated that among subjects treated
with topical therapy only, poor adherence
occurred in 40% of cases. When a
combination of both systemic and topical
therapies was used, poor adherence to at least
one treatment increased to 60% [5]. Several
different factors affect adherence. Poor
adherence is independently correlated with
young age, at least one adverse reaction, high
Dermatology Life Quality Index score, previous
systemic treatment, lack of improvement as
evaluated by the dermatologist, lack of patient
satisfaction with treatment, lack of knowledge
about acne treatment and consultation with a
primary care physician [5, 6].
Patients prefer topical acne therapies that are
available as gel formulations, can be used once-
daily, are applied with the fingers and can be
stored at room temperature [7]. Furthermore,
fixed-dose combinations provide convenience
for patients, which improves adherence [1].
Patient preference for one container over
another for dispensing their acne treatment
may also impact adherence. However, such data
are limited. A previous study by Fried and
Nighland in acne patients dissatisfied with
their current therapy assessed the impact of a
new acne treatment dispensed from a pump [8].
They found that more than three-quarters of
patients rated the pump as an excellent or very
good way to dispense their medication, and a
similar proportion of patients were very satisfied
or extremely satisfied with the pump treatment
application [8].
Key to a patient’s success on fixed-dose
adapalene–benzoyl peroxide (BPO) gel is
consistent application. This means not only
ensuring patients apply their treatment as
frequently as prescribed, but also ensuring
patients apply the right amount of product
with each application. The use of a pump
delivering a pre-measured and more consistent
amount of drug at each dose may help to
further improve the efficacy of this treatment
option vs. use of less consistent amounts
dispensed from a tube.
The objective of the present study was to
evaluate patient preference for two different
containers used to dispense fixed-dose
adapalene–BPO gel (tube vs. pump).
MATERIALS AND METHODS
Study Design
This open-label study was conducted by two
investigative sites in the US. The total study
duration was 15 days. At baseline (visit 1),
eligible subjects were randomized into two
groups: one was asked to treat their acne using
Epiduo (adapalene 0.1%–BPO 2.5%) gel
(Quebec: Galderma Production Canada, Inc.)
dispensed in either a 45-g laminate tube or a
45-g bottle with a dispensing pump once-daily
(in the evening) for up to 7 days. At week 1 (visit
2), subjects returned to the site and, upon
returning the study product, were given the
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alternative package to use for up to 7 days. At
the end of the second treatment period, subjects
were asked to return the study product to the
site (visit 3), at which time they completed an
online preference survey. All adverse events
(AEs) or product technical complaints were
collected.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
Subject Selection
Eligible subjects had to meet all the inclusion
criteria and none of the exclusion criteria in
order to qualify for enrollment in the study. Key
inclusion criteria were (1) male or female
subjects of any race, aged 12–35 years
inclusive; (2) diagnosis of acne and eligible for
treatment with adapalene–BPO; (3) subject
willingness to use adapalene–BPO dispensed in
either a tube or a pump for up to 7 days and to
switch to using adapalene–BPO dispensed in the
alternative packaging design for up to 7 days;
and (4) informed consent by the subject (or
guardian if\18 years of age) prior to any study-
related procedures. Exclusion criteria included
(1) female subjects who were pregnant, nursing
or planning a pregnancy; and (2) known or
suspected allergy to the study products.
Statistical Analysis
All analyses were performed on the safety
population (all subjects who were enrolled and
received at least one dose of study products). A
total of 300 subjects were planned for
enrollment with the prediction that a
minimum of 200 subjects would complete the
survey. This sample size ensured that the
margin of error was no larger than 7%.
The response to question 1 in the subject
preference survey was summarized as tube or
pump. Question 5 was summarized for all
responses (very satisfied, satisfied, no opinion,
dissatisfied and very dissatisfied) and also
dichotomized responses (satisfied or not
satisfied), with the definition of satisfied being
a response of satisfied or very satisfied. A subject
was classified as not satisfied if the response was
either no opinion, dissatisfied or very
dissatisfied. The Rao–Scott Chi square test was
applied to the responses to questions 3, 4 and 5
to test differences between the responses. An
exact binomial test was used to determine
differences in responses to questions 1, 2 and
the dichotomized version of question 5.
Additionally, responses for questions 2 and the
dichotomized responses of question 5 were
analyzed using Fisher’s Exact test, grouping
subjects according to their response to
question 1. Question 6 was summarized by
frequencies and percentages.
No statistical analyses were conducted on




A total of 300 enrolled subjects receiving at least
one dose of study product were included in the
safety population. Nine subjects (3%) withdrew
from the study at their own request and 291
subjects (97%) completed the study.
Demographic characteristics were comparable
among both groups (Table 1).
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Subject Preference Survey
Among subjects who completed the preference
survey (n = 291), 79.0% (n = 230) preferred the
pump for dispensing adapalene–BPO gel and
21.0% (n = 61) preferred the tube (p\0.001).
Subjects felt that all the statements listed
within the preference survey better described
the pump over the tube. They included that the
pump made it easier to give a consistent
amount for the face every time (81.8%;
n = 238/291; p\0.001) and made it easier to
know how much to apply to the face (74.9%;
n = 218/291; p\0.001). In addition, subjects
reported the pump was easier to use (82.1%;
n = 239/291; p\0.001), did not waste gel
(72.9%; n = 212/291; p\0.001) and made less
of a mess (86.9%; n = 253/291; p\0.001)
(Table 2).
Results were then analyzed according to
subject preference for the pump or the tube.
Among the subset of subjects who preferred the
pump, the main reasons were because it made
less of a mess (95.2%; n = 219/230; p\0.001),
was more convenient to use (93.5%; n = 215/
230; p\0.001) and was easier to use (93.5%;
n = 215/230; p\0.001) (Table 3).
All subjects who completed the survey were
asked to select the characteristics they felt
described the adapalene–BPO pump. The three
characteristics cited most frequently were easy
to use (89.0%; n = 259/291), clean (73.2%;
n = 213/291) and convenient (69.4%; n = 202/
291) (Fig. 1).
A total of 91.8% (n = 267/291) of subjects
were satisfied (very satisfied or satisfied) with
their experience using the pump (p\0.001).
Among subjects who preferred the pump, the
majority of subjects were satisfied (very
satisfied or satisfied) with their experience
using the pump (98.7%; n = 227/230;
p\0.001).
Just over three-quarters of subjects (76.6%;
n = 223/291) stated that they would tell their
Table 1 Demographic characteristics
Characteristic Measure Safety population (n5 300)
Gender Female 178 (59.3%)
Male 122 (40.7%)
Ethnicity Hispanic or Latino 46 (15.3%)
Not Hispanic or Latino 254 (84.7%)
Race White 200 (66.7%)
Black or African American 43 (14.3%)
Asian 19 (6.3%)
American Indian or Alaska Native 5 (1.7%)
Native Hawaiian or Other Paciﬁc Islander 3 (1.0%)
Other or mixed 30 (10.0%)
Age (years) Mean (standard deviation) 21.5 (7.16)
Median 19.5
Min, max 12.0, 35.0
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doctor about their preference for the pump the
next time their doctor prescribed adapalene–
BPO gel (p\0.001). The majority of subjects
(80.1%; n = 233/291) indicated they would
prefer the pump if the tube and pump cost the
same amount (p\0.001).
Table 2 Subject belief on whether statements better described the attributes of the tube or pump
Statement Response All subjects (n5 291) p value*
Easy to know how much to apply to my face Tube 73 (25.1%) \0.001
Pump 218 (74.9%)
Easy to give me a consistent amount for my face every time Tube 53 (18.2%) \0.001
Pump 238 (81.8%)
Does not waste adapalene–BPO gel Tube 79 (27.1%) \0.001
Pump 212 (72.9%)
Does not drip or leak as much Tube 67 (23.0%) \0.001
Pump 224 (77.0%)
Makes less of a mess Tube 38 (13.1%) \0.001
Pump 253 (86.9%)
Easy to store Tube 120 (41.2%) 0.002
Pump 171 (58.8%)
Easy to handle Tube 66 (22.7%) \0.001
Pump 225 (77.3%)
Easy to use Tube 52 (17.9%) \0.001
Pump 239 (82.1%)
Easy to take with me when I’m not home Tube 124 (42.6%) 0.007
Pump 167 (57.4%)
Saves time Tube 56 (19.2%) \0.001
Pump 235 (80.8%)
Makes it easy to follow my doctor’s instructions Tube 68 (23.4%) \0.001
Pump 223 (76.6%)
Attractive looking Tube 35 (12.0%) \0.001
Pump 256 (88.0%)
The one you are more likely to leave out on the counter Tube 57 (19.6%) \0.001
Pump 234 (80.4%)
More convenient to use Tube 59 (20.3%) \0.001
Pump 232 (79.7%)
BPO benzoyl peroxide
* p value was associated with the exact binomial test against the null hypothesis of 50% for each response
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Table 3 Subject belief on whether statements better described the attributes of the tube or pump based on preference for
the tube or pump
Statement Response Product preference p value*
Tube (n5 61) Pump (n5 230)
Easy to know how much to apply to my face Tube 43 (70.5%) 30 (13.0%) \0.001
Pump 18 (29.5%) 200 (87.0%)
Easy to give me a consistent amount for my face every time. Tube 33 (54.1%) 20 (8.7%) \0.001
Pump 28 (45.9%) 210 (91.3%)
Does not waste adapalene–BPO gel Tube 38 (62.3%) 41 (17.8%) \0.001
Pump 23 (37.7%) 189 (82.2%)
Does not drip or leak as much Tube 38 (62.3%) 29 (12.6%) \0.001
Pump 23 (37.7%) 201 (87.4%)
Makes less of a mess Tube 27 (44.3%) 11 (4.8%) \0.001
Pump 34 (55.7%) 219 (95.2%)
Easy to store Tube 43 (70.5%) 77 (33.5%) \0.001
Pump 18 (29.5%) 153 (66.5%)
Easy to handle Tube 37 (60.7%) 29 (12.6%) \0.001
Pump 24 (39.3%) 201 (87.4%)
Easy to use Tube 37 (60.7%) 15 (6.5%) \0.001
Pump 24 (39.3%) 215 (93.5%)
Easy to take with me when I’m not home Tube 47 (77.0%) 77 (33.5%) \0.001
Pump 14 (23.0%) 153 (66.5%)
Saves time Tube 37 (60.7%) 19 (8.3%) \0.001
Pump 24 (39.3%) 211 (91.7%)
Makes it easy to follow my doctor’s instructions Tube 41 (67.2%) 27 (11.7%) \0.001
Pump 20 (32.8%) 203 (88.3%)
Attractive looking Tube 18 (29.5%) 17 (7.4%) \0.001
Pump 43 (70.5%) 213 (92.6%)
The one you are more likely to leave out on the counter Tube 20 (32.8%) 37 (16.1%) 0.006
Pump 41 (67.2%) 193 (83.9%)
More convenient to use Tube 44 (72.1%) 15 (6.5%) \0.001
Pump 17 (27.9%) 215 (93.5%)
BPO benzoyl peroxide
* p value was associated with the Fisher’s exact test against the null hypothesis of the independence between product
preference and survey response
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Adverse Events
In the safety population (n = 300), 13 subjects
(4.3%) reported 22 events. The AEs were mild
(68.2%; n = 15/22) or moderate (31.8%; n = 7/
22) in severity and most considered by the
investigators to be probably related (95.5%;
n = 21/22) to the study medication. The AEs
were classified largely as skin and subcutaneous
tissue disorders (n = 21/22) and included dry
skin (n = 5/22), erythema (n = 2/22), pain of
skin (n = 8/22), pruritus (n = 1/22), rash (n = 1/
22), scab (n = 1/22), skin exfoliation (n = 2/22)
and skin tightness (n = 1/22). One report of a
toothache was deemed definitely unrelated to
the study medication. No serious AEs were
reported and no subjects withdrew from the
study due to an AE.
Product Technical Complaints
There were no product technical complaints
about the dispensing container with a pump.
There was one report of a product technical
complaint about the tube relating to automatic
dispensing of the product.
DISCUSSION
In this analysis of 300 subjects, we
demonstrated that the majority of acne
subjects prefer the pump over the tube for
dispensing adapalene–BPO gel and a similar
proportion would tell their doctor about this
preference at the time of their next prescription.
Furthermore, over 90% of subjects reported
being satisfied or very satisfied with the pump
on a patient self-assessment scale. These results
align with those of another study showing that
86% of patients dissatisfied with their current
acne therapy who received a new treatment
dispensed from a pump were very satisfied or
extremely satisfied with the pump treatment
application at the end of the 12-week study
period [8].
Since poor adherence is independently
correlated with a lack of patient satisfaction
with their acne treatment [5], it is hoped that
use of a pump instead of a tube to dispense
adapalene–BPO gel may further encourage
patient adherence to this treatment option. In
fact, one study has shown that 95% of acne
patients using a pump dispenser over a 3-month
Fig. 1 Characteristics describing the adapalene–benzoyl
peroxide (BPO) gel pump (n = 291) (subjects were asked
to choose all that apply). The ﬁgure shows characteristics
selected by subjects who completed the survey that they felt
described the adapalene–BPO pump
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period took 75–100% of their prescribed doses
[9]. Such findings are important in all acne
patients, but especially when treating patients
with long-term chronic disease who require
maintenance therapy, as good adherence may
help to reduce the risk of relapse. The
combination of two effective medications into
one fixed-dose adapalene–BPO regimen helps to
reduce the complexity of acne management by
reducing the number of treatments a patient
has to remember to take on a daily basis and is
another effective approach to enhancing
adherence [10].
It is important to ensure the patient uses
their medication as directed. Application of the
same amount each time encourages an even
spread and distribution of topical acne
medication on each occasion, which allows for
consistency of application [11]. The use of a
system to deliver a pre-measured amount of
adapalene–BPO gel with each pressure
(approximately 0.5 ml) enables patients to
apply a more consistent dose each time vs. the
tube, i.e. a thin film of gel across the entire
acne-affected areas and not just individual
pimples [12, 13]. Critically, over 90% of
subjects who preferred the pump found it was
an easy way to deliver a consistent amount each
time, helping to optimize patient outcomes [14,
15]. Furthermore, doctors should be able to
more accurately predict how long a prescription
will last when the gel is dispensed from a pump
instead of a tube [11].
In addition to medication use as directed,
successful management of acne also involves
choosing the right medication. As such, efficacy
is a critical parameter when treating patients
with acne and individuals often need long-term
maintenance therapy [1, 2, 14, 15]. Treatment
with adapalene–BPO results in a significant
reduction in total, inflammatory and non-
inflammatory lesions at week 1. Further
improvements observed to week 12 can be
sustained to week 52 [16–18]. In cases of more
severe disease, there is clinical benefit in
combining adapalene–BPO with lymecycline
or doxycycline for 12 weeks [19, 20]. Longer
term adapalene–BPO treatment for a further
6 months prevents relapse and continues to
reduce acne lesions over the same timeframe
[14, 15].
Just over 75% of all subjects stated that use of
the pump instead of the tube made it easier to
follow their doctor’s instructions, which
increased to over 88% in subjects who
preferred the pump. As a result, patients will
be using the gel as directed and are more likely
to have a safer treatment experience. Use of a
more consistent amount of adapalene–BPO gel
dispensed from a pump may help to reduce the
occurrence of adverse reactions, compared with
possible over-application of the gel if dispensed
from a tube [11]. The safety profile of
adapalene–BPO gel demonstrated in this study
is consistent with the findings of previous
studies [17, 18, 21, 22].
Product waste increases the cost of therapy
[11]. Almost three-quarters of subjects preferred
the pump over the tube because it did not result
in as much waste. Product waste may manifest
as drips and leaks from the container and excess
product being dispensed. Use of a pump to
dispense a more consistent amount of
adapalene–BPO gel vs. the tube avoids both of
these potential issues. Furthermore, waste may
also result from medication left in the dispenser
when it appears empty. The pump has a better
product restitution rate compared with the tube
([95% and [90%, respectively) [13, 23].
The open-label study design introduces
significant bias, which limits the
generalizability of the results. However, the
order of the response choices to the survey
questions was randomized to avoid bias. In
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addition, all therapies were authorized so
subjects were able to use previous and
concomitant therapies as part of their
individualized treatment plan. Since the aim
was to assess subject preference for the
dispensing container and not the medication
itself, no diaries were used to assess treatment
compliance. Collation of such information
would have facilitated further analysis of the
impact of the pump as a preferred dispensing
route.
CONCLUSION
Patients prefer using a pump instead of a tube to
dispense adapalene–BPO gel. This delivery
mechanism helps to ensure consistent
application and thus may improve patient
adherence to the prescribed acne treatment
regimen.
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